The market implies a ≈19% probability that WVE prints a "bull" outcome — solving on probability-weighted scenario midpoints with $7.24 spot and $1.4B cap. Our scenario weights put that probability at ≈55%. The gap isn't in the pipeline. Sixteen analysts rate WVE Buy. The fundamental story — RNA editing platform, AATD lead asset, INHBE obesity, GSK collaboration — is well-distributed and well-priced. The gap is in two structural signals that the consensus framing isn't pricing: vol surface and counterparty flow. Both require verification. Both, if verified, define the trade.

Where the mispricing lives

Vol surface. ATM IV reportedly sits at the 8th percentile. At ≈50-70% annualized vol, a 16-DTE straddle implies an absolute move of ≈13%. A probability-weighted realized move — 55% chance of bull (+50-100%), 25% mixed (-10 to +20%), 20% bear (-40 to -60%) — works out to ≈55% absolute. That's a 3-4× discrepancy between what the chain prices and what the binary distribution implies. Even cutting expected realized in half, a straddle still pays ≈2× premium. The vol sellers either don't price the May binary, or are pricing it as no-event despite the public timeline.

Counterparty flow. RA Capital reportedly bought $54.6M (8.77M shares) at $6.22 on March 30 — four days post the WVE-007 readout. Director Takanashi Ken reportedly acquired ≈$28M same week. C-suite 10b5-1 plans are the loud signal; the open-market accumulation is the quiet one. Form 4 transaction code (P vs A/M/F) and RA Capital 13G/13D filing must be confirmed on EDGAR. If verified, retail/momentum sold the post-readout run; specialist money bought the fade.

The fundamental context

The Q1 2026 10-Q (filed April 28) confirmed binary timing held: WVE-006 400mg multidose + 600mg SAD AATD data is now guided to May 2026 (a 4-8 week slip from "Q1"). Cash $544.6M at March 31, Q1 burn $59.6M (≈$238M annualized — in-line with guidance), Q3 2028 runway intact. FDA accepted the Phase 2a INLIGHT IND for WVE-007 (INHBE/obesity) with body weight added as an explicit Phase 2a endpoint. Wave reabsorbed full WVE-006 rights from GSK in February ($35.9M one-time deferred revenue catch-up). No new Item 1A risk factors.

Cash floor: $544.6M / ≈204M shares = ≈$2.67/share. At $7.24, the market is paying ≈$4.57 for the pipeline. That's the asymmetry on the bear side.

The Phase 2a body-weight inclusion is two-edged and worth reconciling. Adding body weight as an endpoint is regulatory pragmatism — Wave is testing against the FDA Jan 2025 Draft Guidance categorical thresholds (≥10/15/20%) rather than fighting them. That's positive on regulatory posture. But Phase 1 monotherapy showed -0.9% body weight at lower-BMI patients. Whether Phase 2a (BMI 35-50) clears categorical thresholds is the open question, and it isn't answered for 12-18 months. Endpoint inclusion is the question being asked. The answer is unresolved.

Why the consensus framing missed it

Cross-ticker class pivot, unsynthesized. ARWR Q1 2026 call leads ARO-INHBE combo data with weight loss (-9.4% combo vs -4.8% tirzepatide alone), body composition supportive. REGN Q4 2025 call dropped trevogrumab from prepared remarks, pivoted to olororepiti monotherapy + PCSK9 — Yancopoulos: "Let else fight extra 1% 2% weight loss." LLY Q4 2025 R&D update silent on bimagrumab. The body-comp obesity class is sectorally pivoting toward body-weight-primary endpoints. Each transcript is public; the synthesis is not. That's why Wave's quiet endpoint pivot reads as innovation in the trade press — but it's convergence, not differentiation. Bear-relevant for WVE-007 monotherapy story, neutral for the May AATD binary that drives near-term variance.

Risks (ranked)

1. Verification failure. If ATM IV is not at the 8th percentile, Takanashi Form 4 is not a P-code, or RA Capital's filing is not on EDGAR, the structural edge collapses to a directional coin flip with no differentiated read.
2. AATD dose-response failure. 400mg SAD showed only 12.8 µM total AAT vs 200mg SAD's 20.6 µM — non-monotonic. If 400mg multidose doesn't rescue (≥20 µM), platform validation breaks and the cash floor stops mattering on a 30-day horizon. -40-60% downside.
3. Equity issuance before May data. The open prediction (sentinel) assigns 92% probability that Wave does not file an S-3 takedown, activate the ATM, or issue convertibles before May 31. Falsifies on any equity-issuing 8-K. Pre-data issuance would invalidate the bull math entirely.
4. WVE-007 path uncertain. Decay risk on the obesity story; secondary to the May binary on near-term variance.

Catalysts (thesis window only)

• April 29, 2026 — Singapore court hearing on Delaware redomiciliation
• May 2026 (≈16 days) — WVE-006 400mg multidose + 600mg SAD data
• Mid-2026 (June-July) — FDA written feedback on WVE-006 accelerated approval pathway

What would change our mind

• IV verification ≥ 50th percentile — vol mispricing thesis is dead.
• Takanashi Form 4 not P-code (A/M/F instead) — flow signal disconfirmed.
• RA Capital 13G/13D not on EDGAR — specialist accumulation thesis fails.

(Separate: a C-suite P-code purchase before May data would upgrade the read by inverting the insider-selling pattern. That's a positive trigger, not a reversal.)

Where the asymmetry is

If verification holds, the asymmetry is in derivatives, not the underlying. A long straddle (May 16 or June 20 expiry) at 8th-percentile IV captures the realized-vs-implied gap with bounded loss; the directional play forces a coin-flip on the binary outcome with no differentiated edge. If verification fails, neither expression has structural edge, and the position is consensus exposure at best. The verification queue is the gating item.

Evidence

Two structural signals require verification before sizing (options chain, EDGAR). Everything below is SEC-primary confirmed.